BMO Capital Markets Reiterates "Outperform" Rating for Genmab A/S (NASDAQ:GMAB)

BMO Capital Markets restated their outperform rating on shares of Genmab A/S (NASDAQ:GMAB - Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $48.00 target price on the stock, up from their previous target price of $46.00.

Other equities analysts have also issued research reports about the stock. Truist Financial reduced their price target on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, September 9th. Redburn Atlantic began coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They set a "buy" rating for the company. Morgan Stanley reissued an "equal weight" rating and set a $31.00 price objective on shares of Genmab A/S in a report on Wednesday, September 11th. JPMorgan Chase & Co. restated a "neutral" rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Finally, Royal Bank of Canada upgraded Genmab A/S from a "sector perform" rating to an "outperform" rating in a research note on Monday, July 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Genmab A/S presently has a consensus rating of "Moderate Buy" and an average target price of $45.20.

Genmab A/S Stock Down 0.1 %

Genmab A/S stock traded down $0.03 during midday trading on Friday, hitting $23.08. 1,560,527 shares of the stock were exchanged, compared to its average volume of 675,316. Genmab A/S has a 52-week low of $21.90 and a 52-week high of $32.89. The business's 50-day moving average price is $24.39 and its 200-day moving average price is $26.41. The stock has a market capitalization of $15.27 billion, a price-to-earnings ratio of 19.07, a price-to-earnings-growth ratio of 0.68 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). The business had revenue of $779.50 million during the quarter, compared to analysts' expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. On average, sell-side analysts predict that Genmab A/S will post 1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently made changes to their positions in the stock. Capital International Investors lifted its stake in Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company's stock worth $130,805,000 after purchasing an additional 315,355 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock valued at $36,752,000 after purchasing an additional 103,859 shares in the last quarter. DDD Partners LLC bought a new position in shares of Genmab A/S during the 2nd quarter valued at $8,860,000. Cubist Systematic Strategies LLC raised its position in Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock worth $7,000,000 after purchasing an additional 145,689 shares during the period. Finally, Oppenheimer Asset Management Inc. lifted its stake in Genmab A/S by 6.5% in the third quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company's stock worth $5,662,000 after purchasing an additional 14,165 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.